Pfizer licenses stomach therapy ... | Chemical & Engineering News
Volume 85 Issue 1 | p. 12 | Concentrates
Issue Date: January 1, 2007

Pfizer licenses stomach therapy ...

Department: Business

Pfizer has licensed Kosan Biosciences' motilin agonist program, including Kosan's KOS-2187, which is being studied in gastrointestinal diseases. Kosan will receive an up-front payment of $12.5 million and could receive payments up to $250 million, plus royalties, for the successful development of the compound for one indication. Pfizer has also expanded its therapeutic antibody collaboration with MorphoSys to the end of 2011. The potential value of the collaboration to MorphoSys is now more than $100 million, plus royalties.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment